These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 6984544)

  • 1. Disseminated intravascular coagulation after infusion of FEIBA (factor VIII inhibitor bypassing activity) in a patient with acquired haemophilia.
    Rodeghiero F; Castronovo S; Dini E
    Thromb Haemost; 1982 Dec; 48(3):339-40. PubMed ID: 6984544
    [No Abstract]   [Full Text] [Related]  

  • 2. Laboratory evidence of DIC under FEIBA treatment of a hemophilic patient with intracranial bleeding and high titre factor VIII inhibitor.
    Fukui H; Fujimura Y; Takahashi Y; Mikami S; Yoshioka A
    Thromb Res; 1981 Apr 1-15; 22(1-2):177-84. PubMed ID: 6794176
    [No Abstract]   [Full Text] [Related]  

  • 3. The use of FEIBA (factor eight inhibitor bypassing activity) in cataract extraction in hemophilia A patient with inhibitor.
    Tourbaf KD; Dunlap BE; Ambrus JL; Rodman DJ; Atwal AJ
    J Med; 1982; 13(5-6):399-410. PubMed ID: 6820380
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Thrombogenicity associated with factor IX complex concentrates.
    Lusher JM
    Semin Hematol; 1991 Jul; 28(3 Suppl 6):3-5. PubMed ID: 1780767
    [No Abstract]   [Full Text] [Related]  

  • 5. Factor IX thrombogenicity: in vivo effects on coagulation activation and a case report of disseminated intravascular coagulation.
    Small M; Lowe GD; Douglas JT; Forbes CD; Prentice CR
    Thromb Haemost; 1982 Aug; 48(1):76-7. PubMed ID: 7135346
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX].
    Iizuka A; Kuwashima M; Nagao T
    Nihon Ketsueki Gakkai Zasshi; 1982 Sep; 45(5):987-92. PubMed ID: 6818811
    [No Abstract]   [Full Text] [Related]  

  • 7. Effects of low-dose 'factor VIII inhibitor bypassing activity (FEIBA)' in resistant haemophilia.
    Zwahlen H; Beck EA
    Acta Haematol; 1980; 64(1):12-7. PubMed ID: 6774572
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A case of sigmoid cancer who acquired factor V inhibitor producibility and treated with factor VIII inhibitor bypassing activity preparation FEIBA--with bibliographic review (author's transl)].
    Abe T; Kazama M; Itokazu K; Kinoshita T; Ogushi T; Tahara C; Fukui H
    Rinsho Ketsueki; 1980 Nov; 21(11):1664-73. PubMed ID: 6782277
    [No Abstract]   [Full Text] [Related]  

  • 9. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the United Kingdom Haemophilia Centre Doctors Organisation.
    Hay CR; Brown S; Collins PW; Keeling DM; Liesner R
    Br J Haematol; 2006 Jun; 133(6):591-605. PubMed ID: 16704433
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Clinical use of factor IX concentrates].
    Nyman D
    Schweiz Med Wochenschr; 1975 Sep; 105(37):1188-90. PubMed ID: 1215901
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Conjectures on factor VIII bypassing activity.
    Aronson DL
    Prog Clin Biol Res; 1981; 72():103-21. PubMed ID: 6977778
    [No Abstract]   [Full Text] [Related]  

  • 12. [The problem of factor VIII inhibitors in patients with congenital coagulopathies].
    Klare M
    Z Gesamte Inn Med; 1983 Jan; 38(2):47-50. PubMed ID: 6407220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison between a serum fraction and FEIBA fraction in haemophilia.
    Hutton RA; Dormandy K; Nour-Eldin F
    New Istanbul Contrib Clin Sci; 1980; 13(1):9-22. PubMed ID: 6774316
    [No Abstract]   [Full Text] [Related]  

  • 14. [Therapy of immuninhibitor hemophilia A with FEIBA plasma fraction].
    István L; Bariska I; Marton E
    Orv Hetil; 1980 Dec; 121(51):3131-5. PubMed ID: 6784062
    [No Abstract]   [Full Text] [Related]  

  • 15. [Non-activated and activated prothrombin complex concentrates, Proplex and Feiba, in the treatment of a hemophilia B patient with high titer inhibitor against factor IX].
    Niiya K; Hirose S; Taguchi H; Miyoshi I
    Rinsho Ketsueki; 1985 Jun; 26(6):980-4. PubMed ID: 3877825
    [No Abstract]   [Full Text] [Related]  

  • 16. Treatment of hemophilia complicated by inhibitors.
    Scand J Haematol Suppl; 1980; 35():135-64. PubMed ID: 6770458
    [No Abstract]   [Full Text] [Related]  

  • 17. Disseminated intravascular coagulation in a patient with haemophilia B during factor IX replacement therapy.
    Ohga S; Saito M; Matsukazi A; Kai T; Ueda K
    Br J Haematol; 1993 Jun; 84(2):343-5. PubMed ID: 8398841
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activated F IX concentrate (FEIBA) used in the treatment of haemophilic patients with antibody to F VIII.
    Stenbjerg S; Jørgensen J
    Acta Med Scand; 1978; 203(6):471-6. PubMed ID: 665313
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful major and minor surgery using factor VIII inhibitor bypassing activity in patients with haemophilia A and inhibitors.
    Lauroua P; Ferrer AM; Guérin V
    Haemophilia; 2009 Nov; 15(6):1300-7. PubMed ID: 19659794
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [New looks in the treatment of haemophilia "A" patients with specific factor VIII inhibitors (author's transl)].
    Magallón Martínez M; Ortega Blanco F; Gago de Luis J; Jover Sagarra S; Martin Villar J
    Sangre (Barc); 1978; 23(1):47-63. PubMed ID: 345497
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.